Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure.
This randomized, placebo-controlled trial showed that levosimendan administration causes a significant reduction of circulating proinflammatory cytokine interleukin-6 and soluble apoptosis mediators, such as soluble Fas and Fas ligand in patients with decompensated heart failure. These immunomodulatory effects may lead to improvement of symptoms and echocardiographic markers of cardiac contractile performance in these patients.
Parissis
John T
JT
Second Department of Cardiology, Amalia Fleming Hospital, Athens, Greece. j.parissis@yahoo.com
Adamopoulos
Stamatis
S
Antoniades
Charalambos
C
Kostakis
George
G
Rigas
Antonios
A
Kyrzopoulos
Stamos
S
Iliodromitis
Efstathios
E
Kremastinos
Dimitrios
D
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000368:Aged; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D053222:Fas Ligand Protein; D005260:Female; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D006835:Hydrazones / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D015850:Interleukin-6 / Q000097:blood*; D008297:Male; D008562:Membrane Glycoproteins / Q000097:blood / Q000187:drug effects*; D011724:Pyridazines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000077464:Simendan; D016277:Ventricular Function, Left / Q000187:drug effects
D000276:Adjuvants, Immunologic; D002316:Cardiotonic Agents; C505661:FASLG protein, human; D053222:Fas Ligand Protein; D006835:Hydrazones; D015850:Interleukin-6; D008562:Membrane Glycoproteins; D011724:Pyridazines; D000077464:Simendan